ASH 2020 Focus on Lymphoma
Coverage from the 62nd ASH Annual Meeting & Exposition

Focus on Lymphoma

The 62nd ASH Annual Meeting and Exposition—originally to be held in San Diego—will be held virtually this year from December 5-8, 2020. Attendees will have access to thousands of scientific abstracts highlighting cutting-edge research in hematology in a state-of-the-art virtual exhibit hall. This conference is an opportunity to enhance your practice through educational programs while exploring new research presented by hematologists around the world. Check out highlights from the upcoming conferences to help you make the most of your time at ASH.

Featured Content

Frontline Brentuximab Vedotin Shows Promise in Older Hodgkin Lymphoma Patients

New data found that older patients with classical Hodgkin lymphoma (cHL) and multiple comorbidities had very high response rates and a clinically meaningful improvement in progression-free survival when treated with brentuximab vedotin monotherapy or combined with other single agents compared to combination chemotherapy (Abstract 471).

Read More

CAR T Cells Induce High Responses in Relapsed Refractory Indolent NonHodgkin Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy yields considerable and durable clinical benefits in patients with indolent non-Hodgkin Lymphoma (iNHL), with a manageable safety profile.

Read More

Circulating Tumor DNA as a Potential Prognostic Marker for Aggressive B-Cell Lymphomas

Diffuse large B cell lymphoma (DLBCL) is a particularly aggressive B-cell lymphoma that is also the most prevalent non-Hodgkin lymphoma. Autologous stem cell transplantation (ASCT) has proven to be an effective intervention for many patients with relapsed or refractory DLBCL, curing them of their disease. 

Read More

A New Biomarker for Patients With Aggressive Lymphoma

A new biomarker discovered by a team that includes researchers from Penn Medicine identifies patients with an aggressive form of lymphoma unlikely to respond to the targeted treatment ibrutinib. It’s a clinically actionable finding that will help guide physicians toward the right treatment for patients with activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) who harbor these newly exposed mutations in the BCL10 gene.

Read More

Breakthrough Cell Therapy Treatment Shows Early Promise

It was one of the most surprising moments of Elizabeth Budde’s career. As Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, Budde, MD, and other researchers were treating a lymphoma patient with IGM-2323, a novel type of bispecific antibody shown to be effective in lab studies. This patient, one of the first eight humans to receive this treatment, had already been unsuccessfully treated with CAR T-cell therapy. IGM-2323 was likely their last chance at survival.

Read More

CAR T-Cell Engineering May Enhance Responses in Large B-Cell Lymphoma

Stanford University researchers have identified tumor-specific factors driving inherent or acquired resistance to chimeric antigen receptor (CAR) T cells in large B-cell lymphomas (LBCL). They have also discovered that CD58 status is an important biomarker for durable response to CAR T cells.

Read More

New Treatment for Achieving Hodgkin Lymphoma Remission

Adding nivolumab to the treatment plan of patients with primary refractory or relapsed Hodgkin lymphoma may expand their life span, according to early results from a study presented at the 2020 ASH Annual Meeting and Exposition (Abstract 472). In new research, Alex Herrera, MD, a hematologist and oncologist at City of Hope, revealed only three of the 59 patients relapsed.

Read More